17.99
Schlusskurs vom Vortag:
$19.37
Offen:
$18.2
24-Stunden-Volumen:
313.26K
Relative Volume:
1.20
Marktkapitalisierung:
$256.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+22.13%
1M Leistung:
+67.04%
6M Leistung:
-47.88%
1J Leistung:
-46.65%
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NGNE
Neurogene Inc
|
17.99 | 210.08M | 0 | 0 | 0 | 0.00 |
![]()
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
2024-03-21 | Eingeleitet | William Blair | Outperform |
2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
2024-01-05 | Eingeleitet | Stifel | Buy |
2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com Nigeria
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World
Neurogene Shares Drop After Downgrade From Baird - marketscreener.com
Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha
Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus
Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia
Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com Nigeria
Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World
Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com
HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus
Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus
Wells Fargo & Company MN Purchases 1,397 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Barclays PLC Has $401,000 Position in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Q1 Earnings Snapshot - San Francisco Chronicle
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2025 - BioSpace
Neurogene Reports Q1 2025 Financial Results and Advances Rett Syndrome Gene Therapy - TipRanks
NEUROGENE Earnings Results: $NGNE Reports Quarterly Earnings - Nasdaq
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
Daily Market Movement: Neurogene Inc (NGNE) Sees a -13.63 Decrease, Closing at 13.05 - DWinneX
10,475 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Mariner LLC - Defense World
Neurogene Inc expected to post a loss of $1.06 a shareEarnings Preview - TradingView
Neurogene (NGNE) Expected to Announce Earnings on Friday - Defense World
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting - BioSpace
Neurogene Announces Upcoming Oral Presentation On Monitoring And Treatment To Reverse Rare Complication Of High Dose Gene Therapy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Neurogene Inc. (NGNE)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Neurogene Inc. (NASDAQ:NGNE) Shares Acquired by Geode Capital Management LLC - Defense World
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $47.20 - Defense World
Wellington Management Group LLP Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - The AM Reporter
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform By Investing.com - Investing.com South Africa
Wellington Management Group LLP Increases Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
JPMorgan Chase & Co. Purchases 476,418 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NASDAQ:NGNE) Given New $16.00 Price Target at BMO Capital Markets - Defense World
Neurogene Inc. Amends Agreement, Issues Warrants By Investing.com - Investing.com South Africa
Neurogene Inc. Amends Agreement, Issues Warrants - Investing.com
Neurogene Amends Agreement With Baker Bros To Increase Nomination Threshold - marketscreener.com
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform - Investing.com Canada
NGNE Stock Sees Decline of Approximately -13.67% in Last Five Days - knoxdaily.com
NGNE stock touches 52-week low at $8.35 amid market challenges - Investing.com Australia
NGNE stock touches 52-week low at $8.35 amid market challenges By Investing.com - Investing.com South Africa
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome - BioSpace
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):